Advertisement

Topics

Kite Reports Second Quarter 2017 Financial Results

08:00 EDT 8 Aug 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Filed Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel for Potential EU Approval and Launch in 2018 Submitted Investigational New Drug Application for...

Other Sources for this Article

KITE CONTACT:
Christine Cassiano
SVP, Corporate Communications & Investor Relations
ccassiano@kitepharma.com
or
Greg Mann
VP, Investor Relations
gmann@kitepharma.com

NEXT ARTICLE

More From BioPortfolio on "Kite Reports Second Quarter 2017 Financial Results"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...